Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 9, 2006, Pages 981-987

  Yau, Kawai ^a   Price, Patricia ^a   Pillai, Radhakrishma G ^a   Aboagye, Eric ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Molecular imaging; Nucleosides; PET scan; Radiopharmaceuticals

Indexed keywords

CARBON 11; CISPLATIN; FLUOROURACIL; NOLATREXED; RADIOPHARMACEUTICAL AGENT; THYMIDINE; THYMIDINE H 3; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TRACER; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL STRAIN HT29; CELL STRAIN RIF 1; CELL TRANSPORT; CELL VIABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG UPTAKE; ENZYME INHIBITION; FIBROSARCOMA; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE;

ADENOCARCINOMA; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; ENZYME INHIBITORS; FIBROSARCOMA; FLUOROURACIL; HT29 CELLS; HUMANS; QUINAZOLINES; RADIOPHARMACEUTICALS; THYMIDINE; THYMIDYLATE SYNTHASE; TIME FACTORS; TRITIUM;

EID: 33747040576     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0060-8     Document Type: Article

References (29)

1. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-456
2. 11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003;95(9):675-682
3. Curtin NJ, Harris AL, Aherne GW. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 1991;51:2346-2352
4. Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995;6:871-881
5. Ford HE, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, et al. Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-Fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 2002;8:103-109
6. Peters GJ, Van der Wilt CL, Can Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-2042
7. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11(8):2785-27808
8. Weber G, Nagai M, Natsumeda Y, Ichikawa S, Nakamura H, Eble JN, et al. Regulation of de novo and salvage pathways in chemotherapy. Adv Enzyme Regul 1991;31:45-67
9. Kinsella AR, Smith D, Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 1997;75:935-945
10. Romain S, Spyratos F, Descotes F, Daver A, Rostaing-Puissant B, Bougnoux P, et al. Prognostic of DNA-synthesising enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicancer study. Int J Cancer 2000;87:860-868
11. INK4a- mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil. Pathol Int 2004;54:564-575
12. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, et al. Cellular pharmacology and in vivo activity of a new anticancer agent ZD9331: a water soluble non polyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 1997;3:911-921
13. Jones TR, Calvert AH, Jackman AL, Brown SJ, Jones M, Harrap KR. A potent antitumour quinazoline inhibitor of thymidylate synthase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer 1981;17:11-19
14. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolates that inhibits multiple folate requiring enzymes. Cancer Res 1997;57:1116-1123
15. Webber S, Bartlett CA, Boritzki TJ, Hillard JA, Howland EF, Johnston AL, et al. AG337, a novel lipophylic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 1996;37:509-517
16. Jackman AL, Taylor GA, Calvert AH, Harrap KR. Modulation of antimetabolites effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthase inhibitor, CB3717. Biochem Pharmacol 1984;33:3269-3275
17. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51:5579-5586
18. Webber SE, Bleckman TM, Attard J, Deal JG, Kathardekar V, Welsh KM. Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem 1993;36:733-746
19. Pil PM, Lippard SJ. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 1992;256:234-237
20. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3(7):207-212
21. Yamauchi T, Keating MJ, Plunkett W. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Therap 2002;1:287-294
22. 18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002;29:1174-1181
23. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29(11):1462-1469
24. Webber S, Bartlett CA, Boritzki TJ, Hilliard JA, Howland EF, Johnston AL, et al. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 1996;37:509-517
25. Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, et al. Thymidylate synthase and drug resistance. Eur J Cancer 1995;31A(7-8):1299-1305
26. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6(10):1653-1664
27. Aboagye EO, Price PM, Jones T. In vivo pharmacokinetics and pharmacodynamics using positron emission tomography, PET. Drug Discov Today 2001;6:293-302
28. Aboagye EO. PET imaging of small animals in anticancer drug development. Mol Imaging Biol 2005;7:53-58
29. Kenny LM, Aboagye EO, Price PM. PET imaging of cell proliferation in oncology. Clin Oncol 2004;16:1176-1185